Edition:
United Kingdom

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

4.25USD
22 Nov 2017
Change (% chg)

$0.31 (+7.87%)
Prev Close
$3.94
Open
$4.00
Day's High
$4.47
Day's Low
$4.00
Volume
611,972
Avg. Vol
363,971
52-wk High
$4.47
52-wk Low
$1.94

Select another date:

Tue, Nov 7 2017

BRIEF-Rigel announces Q3 loss of $0.14 per share

* Rigel announces third quarter 2017 financial results and provides company update

BRIEF-Rigel announces pricing of public offering of common stock

* Says public offering of 18.1 million common shares priced at $3.35 per share Source text for Eikon: Further company coverage:

BRIEF-Rigel announces proposed public offering of common stock

* Rigel Pharmaceuticals Inc - intends to offer and sell up to $40 million of shares of its common stock in an underwritten public offering

BRIEF-RIGEL PHARMACEUTICALS SAYS FOSTAMATINIB MEETS PRE-SPECIFIED GOAL IN STAGE 1 OF AIHA PHASE 2 STUDY

* FOSTAMATINIB MEETS PRE-SPECIFIED PRIMARY ENDPOINT IN STAGE 1 OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) PHASE 2 STUDY

BRIEF-Rigel provides update on FDA review of fostamatinib for ITP

* Rigel provides update on FDA review of fostamatinib for ITP

BRIEF-Rigel Q2 loss per share $0.16

* Rigel announces second quarter 2017 financial results and provides company update

BRIEF-FDA accepts Rigel's NDA for Tavalisse

* FDA accepts Rigel's New Drug Application for Tavalisse™ (fostamatinib disodium) for the treatment of chronic ITP

BRIEF-Rigel Pharmaceuticals enters into amendment to controlled equity offerings sales agreement

* Entered into amendment no. 1 to controlled equity offerings sales agreement, dated august 18, 2015 - SEC filing

Select another date: